A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer

Robertson, John F.R.; Evans, Abigail; Henschen, Stephan; Kirwan, Cliona C.; Jahan, Ali; Kenny, Laura M.; Dixon, J. Michael; Schmid, Peter; Kothari, Ashutosh; Mohamed, Omar; Fasching, Peter A.; Cheung, Kwok Leung; Wuerstlein, Rachel; Carroll, Danielle; Klinowska, Teresa; Lindemann, Justin P.O.; MacDonald, Alexander; Mather, Richard; Maudsley, Rhiannon; Moschetta, Michele; Nikolaou, Myria; Roudier, Martine P.; Sarvotham, Tinnu; Schiavon, Gaia; Zhou, Diansong; Zhou, Li; Harbeck, Nadia

doi:10.1158/1078-0432.CCR-19-3387

All Outputs (4)

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial (2020)
Journal Article
Smith, I., Robertson, J., Kilburn, L., Wilcox, M., Evans, A., Holcombe, C., …Dowsett, M. (2020). Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncology, 21(11), 1443-1454. https://doi.org/10.1016/S1470-2045%2820%2930458-7

Background: Preoperative and perioperative aromatase inhibitor (POAI) therapy has the potential to improve outcomes in women with operable oestrogen receptor-positive primary breast cancer. It has also been suggested that tumour Ki67 values after 2 w... Read More about Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.

Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance (2020)
Journal Article
Campbell, C., Mathew, J., Ellis, I. O., Bradbury, I., Borgquist, S., Elebro, K., …Robertson, J. F. R. (2020). Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance. Translational Breast Cancer Research, 1, Article 29. https://doi.org/10.21037/tbcr-20-31

Background: It remains clinically important to identify ER positive breast cancers likely to respond to tamoxifen (TAM) and so we aimed to select a group of biomarkers able to predict response. We also assessed whether data from different sample type... Read More about Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance.

Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging (2020)
Journal Article
Sullivan, F. M., Mair, F. S., Anderson, W., Armory, P., Briggs, A., Chew, C., …Schembri, S. (2021). Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging. European Respiratory Journal, 57(1), Article 2000670. https://doi.org/10.1183/13993003.00670-2020

The EarlyCDT-Lung test is a high specificity blood-based autoantibody biomarker that could contribute to predicting lung cancer risk. Here we report on the results of a phase IV biomarker evaluation of whether using the EarlyCDT-Lung test and any sub... Read More about Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging.

A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer (2020)
Journal Article
Robertson, J. F., Evans, A., Henschen, S., Kirwan, C. C., Jahan, A., Kenny, L. M., …Harbeck, N. (2020). A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer. Clinical Cancer Research, 26(16), 4242-4249. https://doi.org/10.1158/1078-0432.CCR-19-3387

©2020 American Association for Cancer Research. PURPOSE: Fulvestrant, the first-in-class selective estrogen receptor (ER) degrader (SERD), is clinically effective in patients with ER+ breast cancer, but it has administration and pharmacokinetic limit... Read More about A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer.